Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Halozyme Therapeutics
HALO
5
Lantheus
LNTH
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -6.75%976.09M | 11.68%4.5B | 23.92%1.21B | 9.23%1.14B | 9.44%1.11B | 4.61%1.05B | -2.37%4.03B | -20.08%972.59M | 3.30%1.05B | -2.56%1.01B |
Operating revenue | -6.75%976.09M | 11.68%4.5B | 23.92%1.21B | 9.23%1.14B | 9.44%1.11B | 4.61%1.05B | -2.37%4.03B | -20.08%972.59M | 3.30%1.05B | -2.56%1.01B |
Cost of revenue | -5.25%723.31M | 9.66%3.31B | 24.75%908.45M | 9.00%833.47M | 5.91%800.5M | -0.33%763.36M | -2.36%3.01B | -22.73%728.2M | 3.19%764.64M | -0.07%755.83M |
Gross profit | -10.79%252.78M | 17.66%1.2B | 21.46%296.83M | 9.83%309.44M | 19.79%309.28M | 20.76%283.34M | -2.39%1.02B | -10.98%244.39M | 3.61%281.73M | -9.18%258.18M |
Operating expense | 1.67%111.86M | 14.15%492.8M | 15.97%132.83M | 16.28%127.45M | 13.92%122.49M | 9.98%110.02M | 6.23%431.71M | 3.99%114.54M | 4.76%109.6M | 6.02%107.53M |
Selling and administrative expenses | 1.67%111.86M | 14.15%492.8M | 15.97%132.83M | 16.28%127.45M | 13.92%122.49M | 9.98%110.02M | 6.23%431.71M | 3.99%114.54M | 4.76%109.6M | 6.02%107.53M |
-Selling and marketing expense | -2.14%52.79M | 12.17%234.37M | 15.70%62.78M | 10.10%59.16M | 12.77%58.5M | 9.90%53.94M | 9.06%208.94M | -5.77%54.26M | 15.88%53.74M | 12.26%51.87M |
-General and administrative expense | 5.33%59.07M | 16.01%258.42M | 16.21%70.06M | 22.23%68.29M | 14.99%63.99M | 10.05%56.08M | 3.70%222.77M | 14.68%60.28M | -4.09%55.87M | 0.79%55.65M |
Operating profit | -18.69%140.92M | 20.24%706.09M | 26.30%163.99M | 5.73%181.99M | 23.98%186.79M | 28.78%173.32M | -7.88%587.22M | -21.01%129.85M | 2.89%172.13M | -17.61%150.66M |
Net non-operating interest income expense | -24.90%5.2M | 37.42%27.51M | -19.23%6.57M | 14.50%6.68M | 57.34%7.35M | 398.20%6.92M | 989.87%20.02M | 4,494.05%8.13M | 932.24%5.83M | 773.88%4.67M |
Total other finance cost | 24.90%-5.2M | -37.42%-27.51M | 19.23%-6.57M | -14.50%-6.68M | -57.34%-7.35M | -398.20%-6.92M | -989.87%-20.02M | -4,494.05%-8.13M | -932.24%-5.83M | -773.88%-4.67M |
Other net income (expense) | 450.00%33K | 90.91%-1K | -1K | 2,700.00%28K | ||||||
Other non- operating income (expenses) | ---- | ---- | ---- | ---- | ---- | ---- | 450.00%33K | 90.91%-1K | ---1K | 2,700.00%28K |
Income before tax | -18.93%146.12M | 20.80%733.61M | 23.62%170.56M | 6.02%188.67M | 24.96%194.14M | 32.55%180.24M | -4.40%607.28M | -15.97%137.97M | 6.82%177.96M | -14.72%155.36M |
Income tax | -17.29%34.88M | 19.71%169.88M | 13.45%37.09M | 10.98%43.22M | 26.87%47.39M | 28.14%42.18M | -1.82%141.91M | -3.26%32.69M | 11.27%38.95M | -17.60%37.36M |
Net income | -19.43%111.24M | 21.14%563.73M | 26.77%133.47M | 4.63%145.45M | 24.36%146.75M | 33.95%138.06M | -5.16%465.37M | -19.26%105.28M | 5.64%139.02M | -13.77%118M |
Net income continuous Operations | -19.43%111.24M | 21.14%563.73M | 26.77%133.47M | 4.63%145.45M | 24.36%146.75M | 33.95%138.06M | -5.16%465.37M | -19.26%105.28M | 5.64%139.02M | -13.77%118M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -19.43%111.24M | 21.14%563.73M | 26.77%133.47M | 4.63%145.45M | 24.36%146.75M | 33.95%138.06M | -5.16%465.37M | -19.26%105.28M | 5.64%139.02M | -13.77%118M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -19.43%111.24M | 21.14%563.73M | 26.77%133.47M | 4.63%145.45M | 24.36%146.75M | 33.95%138.06M | -5.16%465.37M | -19.26%105.28M | 5.64%139.02M | -13.77%118M |
Basic earnings per share | -17.28%4.07 | 21.06%20.29 | 27.97%4.85 | 5.62%5.26 | 23.76%5.26 | 31.90%4.92 | -4.77%16.76 | -20.21%3.79 | 4.62%4.98 | -12.91%4.25 |
Diluted earnings per share | -16.74%3.98 | 21.59%19.71 | 28.69%4.71 | 5.81%5.1 | 24.27%5.12 | 31.32%4.78 | -5.97%16.21 | -21.29%3.66 | 3.21%4.82 | -13.99%4.12 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |